Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Trial of Non-inferiority Comparing RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis

NCT05758831 is registered in ClinicalTrials.gov with Rennes University Hospital as lead sponsor.

NCT NCT05758831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05758831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Trial of Non-inferiority Comparing RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis
Lead sponsor
Rennes University Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
June 1, 2023
Completion date
May 1, 2030
Enrollment
386 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing-remitting multiple sclerosis